Article
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
European journal of cancer (Oxford, England : 1990) - 1 Sept 2013
Richards Donald, Kocs Darren M, Spira Alexander I, David McCollum A, Diab Sami, Hecker Lanny I, Cohn Allen, Zhan Feng, Asmar Lina
Abstract excerpt
BACKGROUND: Patients with advanced adenocarcinoma of the gastroesophageal junction/stomach are treated by combination chemotherapy, with minimal improvements in survival. We evaluated adding cetuximab to combination chemotherapy in these patients. METHODS: The primary objective was progression-free survival. Secondary objectives were response rate, time to response, duration of response and safety. Treatment Arm...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.